• PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor americanpharmaceuticalreview
    January 17, 2020
    PhaseBio Pharmaceuticals has signed an agreement with Viamet Pharmaceuticals and its wholly-owned subsidiary, Selenity Pharmaceuticals, to acquire all of the assets and intellectual property rights related to certain novel aldosterone synthase inhibitors
PharmaSources Customer Service